Abstract
Incidence of Second Cancers in Thyroid Cancer Patients Treated with Radioactive Iodine Ablation: How High Is Really the Risk?
Highlights
Thyroid cancer is the most commonly diagnosed endocrine tumor and the incidence in thyroid cancer is rising throughout the world [1,2]
The relative risk of second primary malignancies in thyroid cancer survivors treated with radioactive iodine ablation (RIA) was significantly increased at 1.19 (95% confidence interval: 1.04-1.36) relative to thyroid cancer survivors not treated with RIA, using a minimum latency period of 2 to 3 years after thyroid cancer diagnosis
In summary, we have provided a short overview of the literature addressing the issue of the incidence of second tumors in differentiated thyroid cancer (DTC) patients in relation to RIA
Summary
Thyroid cancer is the most commonly diagnosed endocrine tumor and the incidence in thyroid cancer is rising throughout the world [1,2]. Because of the excellent prognosis of differentiated thyroid cancer (DTC) and the fact that radiation exposure represents a risk factor for many other cancers, in the last years there has been an exponential attention to the possible association between RIA and second malignancies in thyroid cancer patients [19].
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
